SPDR S&P 500 ETF TRUST

# Signal Note: Driehaus Capital Adds SPY Position Driehaus Capital's $316K initiation of SPY (464 shares) suggests a tactical broadening of equity exposure beyond its core biotech focus, potentially signaling either profit-taking from concentrated biotech holdings or a near-term shift toward defensive large-cap positioning. This move is noteworthy given the firm's historically aggressive growth-biotech mandate and may reflect caution ahead of FDA decisions or market volatility affecting smaller-cap therapeutics. Without concurrent biotech position changes disclosed, the catalyst remains unclear, though it warrants monitoring for follow-up sector rotation moves.